Joyce F. Liu

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.8K citations

Brca1/2 Mutation, Medicine, Cancer Management +10

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum‐Gamez et al. · Journal of the National Comprehensive Cancer Network · 2021 · 688 citations · Full text

Surgical Oncology, Epithelial Ovarian Cancer, Cancer Management +19

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

Kyle C. Strickland, Brooke E. Howitt, Sachet A. Shukla et al. · Oncotarget · 2016 · 612 citations · Full text

Neoantigen Load, Brca1/2-mutation Status, Cancer Immunosurveillance +15

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

Joyce F. Liu, William T. Barry, Michael J. Birrer et al. · The Lancet Oncology · 2014 · 578 citations · Full text

Combination Cediranib, Medicine, Olaparib Versus Olaparib +9